LAWRENCE, Mass., April 28, 2011 /PRNewswire/ — NxStage Medical,
Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products,
today commented on study results presented by the Chronic Disease
Research Group (CDRG) showing daily home hemodialysis with the
NxStage System One is associated with reduced mortality and higher
survival estimates for patients when compared with conventional
thrice-weekly therapy. The retrospective cohort study examines the
mortality and three-year survival rates of 1,873 daily home
hemodialysis (DHHD) patients using the NxStage System One between
2005 and 2007, to a matched cohort of 9,365 in-center hemodialysis
patients from the United States Renal Data System (USRDS) database.
CDRG is a nonprofit division of the Minneapolis Medical Research
Foundation committed to investigating chronic illness to improve
public health, including leveraging USRDS data to conduct
studies.
The study, “Relative Mortality in Daily Home and Matched,
Thrice-Weekly In-Center Hemodialysis Patients,” conducted by CDRG
was presented at this week’s National Kidney Foundation 2011 Spring
Clinical Meeting in Las Vegas.
“This is the first study of its kind to carefully match the
daily home hemodialysis patient population with comparable
in-center dialysis patients based on variables such as comorbidity
and severity of disease, determining the impact on
mortality,” said Dr. Allan Collins, professor of medicine,
University of Minnesota, and director, Chronic Disease Research
Group. “Results show a reduction in mortality for daily home
hemodialysis patients consistent with recently published National
Institutes of Health data on frequent home dialysis versus
in-center therapy, though additional studies are needed to assess
patient hospitalization risk and type of hospitalization.”
Researchers compared daily home hemodialysis patient data with
the
‘/>”/>
